• Topics

  • Formats

In the rapidly evolving landscape of healthcare, the role of medical affairs has become increasingly pivotal. As pharmaceutical companies navigate through the complexities of drug development and market access, integrating value planning into the framework of medical affairs is not just beneficial – it is essential.[1]

Value planning is a powerful process of improving value to the client through the systematic and collaborative analysis of the costs incurred and benefits delivered by different design and construction options. An innovation facilitator will lead the team and chosen stakeholders through a thoughtfully designed and creative problem-solving process. Value planning involves identifying and demonstrating the value of a medical product from clinical, economic, and patient perspectives. This multidimensional approach ensures that new therapies are not only clinically effective but also economically viable and aligned with patient needs and preferences. The goal is to create a comprehensive value proposition that resonates with all stakeholders, including regulators, payers, healthcare providers, and patients.[1]

The integration of value planning into medical affairs is crucial for several reasons. First, it enhances decision-making by enabling medical affairs teams to make informed choices that prioritize patient outcomes and cost-efficiency, leading to better resource allocation and strategy execution. This systematic approach integrates ethical considerations, stakeholder perspectives, and a forward-looking vision, embracing a holistic perspective that includes social responsibility, sustainability, and organizational resilience. Additionally, improved stakeholder engagement is achieved by incorporating input from these stakeholders, fostering stronger relationships with key groups such as physicians, payers, and regulatory bodies. This value-driven approach demonstrates a commitment to evidence-based medicine and transparency, which is essential for achieving sustainable development goals. Furthermore, leveraging value planning provides a competitive advantage in an industry where differentiation is key, attracting investors and partners who value long-term sustainability and social responsibility.[2]

The timing of integrating value planning into medical affairs is contingent upon several factors. Incorporating value planning early in drug development ensures a focus on creating therapies that deliver significant value, aiding in the design of clinical trials that capture relevant endpoints and in preparing compelling dossiers for regulatory submissions. Following significant corporate events, such as mergers or acquisitions, integrating value planning can streamline operations, eliminate redundancies, and ensure that the combined entity operates efficiently towards common objectives. Additionally, strategic reassessment periods, such as regularly scheduled reviews of business strategies, provide opportune moments to reassess and integrate value planning, ensuring that the organization remains agile and responsive to changing market dynamics.[3]

Effectively integrating value planning into medical affairs requires a structured approach. First, clear, measurable objectives must be established that align with the mission and values of the pharmaceutical company, reflecting a commitment to improving patient outcomes and reducing healthcare costs. Next, a comprehensive framework must be developed that outlines the processes, tools, and metrics needed to assess and monitor the value delivered by medical affairs activities. This framework should be adaptable to changes in the healthcare environment. Key stakeholders, including medical affairs staff, clinical researchers, and external experts, must be engaged in the development and implementation of the value planning process, as their input is invaluable in shaping strategies that meet the needs of the healthcare community. Continuous evaluation mechanisms must be implemented using data analytics to track performance against predefined objectives, and strategies must be adjusted as needed to ensure ongoing effectiveness.[3]

Integrating value planning into the development of medical affairs is a strategic move that can significantly enhance the ability of a pharmaceutical company to deliver meaningful value to its stakeholders. As we continue to evolve our understanding of what constitutes true value in healthcare, the role of medical affairs will undoubtedly grow in importance, underscoring the need for a value-centric approach to driving innovation and excellence in patient care.

Become A Certified HEOR Professional – Enrol yourself here!

References:

  1. MAPS. Medical Affairs Launch Excellence Standards Guidance Accessed 06 June 2024. Available from: https://medicalaffairs.org/wp-content/uploads/2021/05/Launch-Excellence-Standards-Guidance.pdf.
  2. Constructing Excellence. Value Management Handbook Accessed 06 June 2024. Available from: https://constructingexcellence.org.uk/wp-content/uploads/2015/03/B1-vp.pdf.
  3. Bahadorestani A, Naderpajouh N, Sadiq R. Planning for sustainable stakeholder engagement based on the assessment of conflicting interests in projects. J Clean Prod. 2019;228:118402. doi:10.1016/j.jclepro.2019.118402.

You are attempting to log out of MyMA

Do you really want to log out?